30. Laffel GL, Braunwald E. thrombolytic therapy. A new strategy fort he treatment of acute myocardial infarction. N. Engl J Med 2001; 311:710-770.

31. The GUSTO Argiographic Investigators: the effects of tissue plasminogen activator, Streptokinase or both on coronary-artery potency ventricular function, and survival after acute myocardial infarction. N Engl J Med 1997; 339:1650-2.

32. American Heart Association. Cardiovascular disease statisties, 2006. (AC Cessed December 7, 2006, at http: // w w w. american heart org.)

33. Pereg D, Behar S, Battler A, Boyko V, Gottlieb S, Leor J. Thrombolytic therapy or primary coronary angioplasty in acute myocardial infarction? Israel Thrombolytic Survey Group]. Harefuah. 2000; 138(11): p. 939-44, 1006.

34. López-Sendón J, López de SA E, Bobadilla JF, Rubio R, Bermejo J, Delcan JL. Efectividad de los diferentes fármacos trombolíticos en el infarto agudo del miocardio. Rev Esp Cardiol 1995; 48:p. 407-37.

35. White H. D. Thrombolytic therapy in the elderly. Lancet 2000; 356:p. 2028-2030.

36. Ritzmann P, Frey R, Ruttimann S. Acute myocardial infarction: time delay from onset of pain to hospital presentation and thrombolysis. Schweiz Med Wochenschr 2000;130(18): p. 657-63.

37. Thiemann D. R, Coresh J, Schulman S. P, Gerstenblith G, Oetgen W. J, Powe N. R. Lack of benefit for intravenous thrombolysis in patients with myocardial infarction who are older than 75 years. Circulation 2000; 101(19): p. 2239-46.

38. López-Sendón J, López de SA E, Bobadilla JF, Rubio R, Bermejo J, Delcan JL. Efectividad de los diferentes fármacos trombolíticos en el infarto agudo del miocardio. Rev Esp Cardiol 1995; 48:p. 407-37.

39. Valladares Carvajal FJ, Iraola Ferrer MD, Aicto Prendes Pr. Trombolisis Tardía. Rev. Cubana Cardiol Cir Cardiovasc 2000; 14(2): 99-106.

40. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio de lla Streptochinasi nell infarto miocardico (GISSI). Lancet 1986;2:397-402